Listed by the USPTO as LI, RUIXIANG
Tech Center 1600 • Art Units: 1634 1646 1674
This examiner grants 60% of resolved cases
LI, RUIXIANG is assigned to Tech Center 1600 and Art Unit 1634. The record includes 1031 resolved cases, a 59.5% allowance rate, and a median of 1018 days to allowance. Interviews are associated with an 18.7% lift, supporting their use when counsel can address a specific dispute through direct technical or claim-focused discussion.
The principal companies are AbbVie Inc., The Board of Trustees of the Leland Stanford Junior University, and Regeneron Pharmaceuticals Inc. The leading firms are Lathrop GPM LLP | Sanofi-Aventis, Patent Law Works, LLP, and STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C. The case volume provides a substantial planning record, while the allowance rate supports careful but active prosecution management.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18670261 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | Non-Final OA | AbbVie Inc. |
| 18710958 | METHODS FOR TREATING ANEMIA OF KIDNEY DISEASE | Non-Final OA | AbbVie Inc. |
| 18359483 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17924612 | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL STORAGE DISORDERS | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18038460 | INHIBITOR OF FIBROSIS PROGRESSION | Non-Final OA | The University of Tokyo |
| 18381745 | DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF | Non-Final OA | AMGEN INC. |
| 17716467 | ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18668446 | HUMANIZED ANTI-IL-1R3 ANTIBODIES | Non-Final OA | SANOFI BIOTECHNOLOGY |
| 19080346 | ENGINEERED PROTEASE ACTIVITY RESPONSIVE RECEPTORS AND USES THEREOF | Final Rejection | TRUSTEES OF BOSTON UNIVERSITY |
| 18037702 | MONITORING MEMBRANE PROTEIN TRAFFICKING FOR DRUG DISCOVERY AND DRUG DEVELOPMENT | Non-Final OA | UNIVERSITY OF HOUSTON SYSTEM |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.5% of resolved applications examined by Ruixiang Li were allowed (1,031 resolved cases), compared with 30.4% across Art Unit 1634 over the last five years.
This examiner's interview lift is +18.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ruixiang Li took 1,018 days on average from filing to allowance.
Ruixiang Li examines applications in Art Unit 1634 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
